P16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma

被引:126
作者
Brown, VL
Harwood, CA
Crook, T
Cronin, JG
Kelsell, DP
Proby, CM
机构
[1] Univ London, St Bartholomews & Royal London Sch Med & Dent, Ctr Cutaneous Res 2, London E1 2AT, England
[2] Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, London, England
关键词
p16(INK4a); p14(ARF); tumor supressor genes; CDKN2A; cutaneous squamous cell carcinoma; gene hyper methylation;
D O I
10.1111/j.0022-202X.2004.22501.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The p16(INK4a) and p14(ARF) tumor suppressor genes (TSGs) are encoded within the CDKN2A locus on chromosome 9p21 and function as cell cycle regulatory proteins in the p53 and RB pathways. Inactivation of these genes by genetic and epigenetic changes has been described in some human cancers, but their importance in cutaneous squamous cell carcinoma (SCC) has not been established. Our detailed examination of 40 cutaneous SCC revealed loss of heterozygosity of 9p21 markers in 32.5% of cases. Mutational analysis confirmed five point mutations in four of 40 SCCs. These mutations changed the amino acid sequence of p16(INK4a) in four tumors and p14(ARF) in three tumors. Promoter methylation of p16(INK4a) and p14(ARF) was detected in 13 of 36 (36%) and 16 of 38 (42%) cases, respectively. Absent protein expression was confirmed by immunohistochemistry in 13 of 16 (82%) of the tumors with biallelic inactivating events. Overall, the frequency of 9p21 alterations was 76% and for both p16(INK4a) and p14(ARF), promoter methylation is the commonest mechanism of gene inactivation. Alterations at this locus were significantly more common in tumors from immunocompetent compared with immunosuppressed individuals. These data confirm the importance of inactivation of p16(INK4a) and p14(ARF) TSGs in the pathogenesis of cutaneous SCCs.
引用
收藏
页码:1284 / 1292
页数:9
相关论文
共 50 条
[41]   Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF [J].
Rizos, H ;
Darmanian, AP ;
Holland, EA ;
Mann, GJ ;
Kefford, RF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (44) :41424-41434
[42]   Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer [J].
Sanchez-Cespedes, M ;
Reed, AL ;
Buta, M ;
Wu, L ;
Westra, WH ;
Herman, JG ;
Yang, SC ;
Jen, J ;
Sidransky, D .
ONCOGENE, 1999, 18 (43) :5843-5849
[43]   Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin [J].
Saridaki, Z ;
Liloglou, T ;
Zafiropoulos, A ;
Koumantaki, E ;
Zoras, O ;
Spandidos, DA .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (04) :638-648
[44]   Role of the INK4a locus in tumor suppression and cell mortality [J].
Serrano, M ;
Lee, HW ;
Chin, L ;
CordonCardo, C ;
Beach, D ;
DePinho, RA .
CELL, 1996, 85 (01) :27-37
[45]   A NEW REGULATORY MOTIF IN CELL-CYCLE CONTROL CAUSING SPECIFIC-INHIBITION OF CYCLIN-D/CDK4 [J].
SERRANO, M ;
HANNON, GJ ;
BEACH, D .
NATURE, 1993, 366 (6456) :704-707
[46]   Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis [J].
Sharpless, NE ;
Bardeesy, N ;
Lee, KH ;
Carrasco, D ;
Castrillon, DH ;
Aguirre, AJ ;
Wu, EA ;
Horner, JW ;
DePinho, RA .
NATURE, 2001, 413 (6851) :86-91
[47]   P16UV mutations in human skin epithelial tumors [J].
Soufir, N ;
Molès, JP ;
Vilmer, C ;
Moch, C ;
Verola, O ;
Rivet, J ;
Tesniere, A ;
Dubertret, L ;
Basset-Seguin, N .
ONCOGENE, 1999, 18 (39) :5477-5481
[48]  
STONE S, 1995, CANCER RES, V55, P2988
[49]   The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 [J].
Stott, FJ ;
Bates, S ;
James, MC ;
McConnell, BB ;
Starborg, M ;
Brookes, S ;
Palmero, I ;
Ryan, K ;
Hara, E ;
Vousden, KH ;
Peters, G .
EMBO JOURNAL, 1998, 17 (17) :5001-5014
[50]   Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53 [J].
Zhang, YP ;
Xiong, Y .
MOLECULAR CELL, 1999, 3 (05) :579-591